Ho I A W, Chan K Y W, Miao L, Shim W S N, Guo C M, Cheang P, Hui K M, Lam P Y P
Laboratory of Cancer Gene Therapy, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore.
Cancer Gene Ther. 2008 Sep;15(9):553-62. doi: 10.1038/cgt.2008.27. Epub 2008 Jun 6.
Human bone marrow-derived mesenchymal stem cells (BM-hMSCs) are nonhematopoietic stem cells that have the potential to differentiate into adipocytes, osteocytes and chondrocytes. Because of its propensity to migrate to the sites of injury and the ability to expand them rapidly, BM-hMSCs have been exploited as potential gene transfer vehicles to deliver therapeutic genes. Herein, we evaluated the feasibility of employing herpes simplex virus type I (HSV-1) amplicon viral vector as a gene delivery vector to BM-hMSCs. High transduction efficiencies were consistently observed in different isolates of BM-hMSCs following infection with HSV-1 amplicon viral vectors. Furthermore, we demonstrated that transduction with HSV-1 amplicon viral vector did not alter the intrinsic properties of the BM-hMSCs. The morphology and cellular proliferation of the transduced BM-hMSCs were not altered. Chromosomal stability, as confirmed by karyotyping and soft agar colony assays, of the transduced BM-hMSCs was not affected. Similarly, transduction with HSV-1 amplicon viral vectors has no effect on the pluripotent differentiation potential and the tumor tropism of BM-hMSCs. Taken together, these results demonstrated that BM-hMSCs could be transduced efficiently by HSV-1 amplicon viral vector in an 'inert' manner and thus enable strategies to express potential therapeutic genes in BM-hMSCs.
人骨髓间充质干细胞(BM-hMSCs)是一种非造血干细胞,具有分化为脂肪细胞、骨细胞和软骨细胞的潜力。由于其易于迁移至损伤部位且能快速扩增,BM-hMSCs已被用作潜在的基因传递载体来递送治疗性基因。在此,我们评估了将I型单纯疱疹病毒(HSV-1)扩增子病毒载体用作BM-hMSCs基因递送载体的可行性。在用HSV-1扩增子病毒载体感染后,在不同分离株的BM-hMSCs中始终观察到高转导效率。此外,我们证明用HSV-1扩增子病毒载体进行转导不会改变BM-hMSCs的内在特性。转导后的BM-hMSCs的形态和细胞增殖未发生改变。通过核型分析和软琼脂集落试验证实,转导后的BM-hMSCs的染色体稳定性未受影响。同样,用HSV-1扩增子病毒载体进行转导对BM-hMSCs的多能分化潜能和肿瘤趋向性没有影响。综上所述,这些结果表明HSV-1扩增子病毒载体能够以“惰性”方式高效转导BM-hMSCs,从而为在BM-hMSCs中表达潜在治疗性基因的策略提供了可能。